NCT07529691 Survey on Physical Activity and Qualify of Life in Fibromuscular Dysplasia
| NCT ID | NCT07529691 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Fibromuscular Dysplasia of Arteries |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2026-04-14 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2026-04-14 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fibromuscular dysplasia (FMD) is a disease of the arteries that is not due to plaque build-up or inflammation. While some patients with FMD are health, some may experience heart attacks, strokes, aneurysms or blood vessel dissection/tearing which can be life-threatening. It predominantly impacts women and younger patients. As a result of this diagnosis, many patients are counseled to restrict or avoid certain physical activities out of concern for provoking or worsening vascular complications. There are no guidelines or consensus recommendations regarding appropriate physical activity for patients with FMD. The lack of consensus may lead to confusion for patients and may negatively impact their quality of life. This study will conduct a large, national survey of patients with FMD to assess the type of physical activity restrictions and impact on quality of life and emotional well-being.
Eligibility Criteria
Inclusion criteria: * Participants with a diagnosis of fibromuscular dysplasia * Age range = 18-100 years Exclusion Criteria: * Subjects who have an inability to complete the electronic consent form or electronic survey for any reason * Subjects who are non-English speaking who cannot read the electronic consent form or electronic survey
Contact & Investigator
Aaron W Aday, MD, MSc
STUDY CHAIR
Vanderbilt University Medical Center
Frequently Asked Questions
Who can join the NCT07529691 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Fibromuscular Dysplasia of Arteries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07529691 currently recruiting?
Yes, NCT07529691 is actively recruiting participants. Contact the research team at amanda.morrison@vumc.org for enrollment information.
Where is the NCT07529691 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT07529691 clinical trial?
NCT07529691 is sponsored by Vanderbilt University Medical Center. The principal investigator is Aaron W Aday, MD, MSc at Vanderbilt University Medical Center. The trial plans to enroll 2,000 participants.